Amyloidosis Drug Improves Outcomes, Survival
Med Page Today
AUGUST 30, 2024
(MedPage Today) -- LONDON -- Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III trial. And the benefits.
Let's personalize your content